Roche, Daiichi Sankyo Win U.S. Approval for Melanoma Drug
This article is for subscribers only.
Roche Holding AG and Daiichi Sankyo Co. won U.S. clearance to sell a pill for melanoma that is among a new wave of medicines developed to fight the deadliest form of skin cancer.
The Food and Drug Administration approved Zelboraf as a therapy for patients whose tumors have spread or can’t be removed surgically, the agency said today in a statement. The drug, also known as vemurafenib, is the second cleared for the disease this year.